The Biologics News and Reports Portal

Show Cart

All Products

Results 1 - 20 of 193

May 2022 Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

400.00 €

May 2022 Claudin 6: A target opportunity to develop effector-enhanced drug modalities

500.00 €

Mar 2022 Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

2,450.00 €

Oct 2021 Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

2,250.00 €

Jun 2021 Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

2,150.00 €

May 2020 Report Package: “Drug the Undruggable” Technologies

4,125.00 €

8,250.00 €

(Discount: 50.00%)

May 2020 Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2,050.00 €

Apr 2020 STING Agonists & Antagonists – Target Pipeline List 04/2020

150.00 €

Mar 2020 Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

90.00 €

Feb 2020 TIGIT-Targeted Immunotherapeutics – Target Pipeline List 02/2020

100.00 €

Feb 2020 Sales Database for Therapeutic Antibodies & Proteins: 1-Year Subscription

200.00 €

Dec 2019 Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

600.00 €

Sep 2019 RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2,050.00 €

Jul 2019 CD137 Costimulatory Receptor Agonists – Target Pipeline List 07/2019

150.00 €

Jun 2019 CD38-Targeted Antibody & Cell Therapy – Target Pipeline List 06/2019

150.00 €

Jun 2019 Report Package: Bispecific Antibodies

2,520.00 €

3,150.00 €

(Discount: 20.00%)

Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End

Shopping cart

Cart empty

Latest report

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Shopping cart

Cart empty

Latest report

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

All Products

May 2022 Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

May 2022 Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Mar 2022 Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Oct 2021 Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Jun 2021 Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

May 2020 Report Package: “Drug the Undruggable” Technologies

May 2020 Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Apr 2020 STING Agonists & Antagonists – Target Pipeline List 04/2020

Mar 2020 Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Feb 2020 TIGIT-Targeted Immunotherapeutics – Target Pipeline List 02/2020

Feb 2020 Sales Database for Therapeutic Antibodies & Proteins: 1-Year Subscription

Dec 2019 Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

Oct 2019 Flat-Rate Subscription to La Merie Publishing Reports

Oct 2019 Competitor Analysis: KRAS Inhibitors

Sep 2019 Competitor Analysis: TGF-beta/Receptor Inhibitors

Sep 2019 Competitor Analysis: RORgamma Antagonists and Agonists

Sep 2019 RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Jul 2019 CD137 Costimulatory Receptor Agonists – Target Pipeline List 07/2019

Jun 2019 CD38-Targeted Antibody & Cell Therapy – Target Pipeline List 06/2019

Jun 2019 Report Package: Bispecific Antibodies

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing